IMGN Financial Facts

Total operating expenses: 44.32M
Research and development support: 1.95M
See Full Income Statement

Current portion of deferred lease incentive: 1.02M
Total liabilities and shareholders' equity: 186.69M
See Full Balance Sheet

Immunogen Inc. (IMGN) Earnings

  |   Expand Research on IMGN
Next EPS Date 8/1/14 EPS Growth Rate -23.1%
Average EPS % Beat Rate +29.0% Revenue Growth Rate +153.8%
Average % Move 1-Wk after EPS -7.4% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
8/1/14 Q414 N/A-$0.32 N/A N/A$9.72M = N/A N/A
4/25/14 Q314 -$0.44-$0.27 -$0.17$6.9M$13.28M = Details
1/31/14 Q214 $0.04-$0.18 +$0.22$30.1M$18.16M = Details
10/25/13 Q114 -$0.13-$0.23 +$0.10$17.2M$12.1M = Details
8/2/13 Q413 -$0.26-$0.30 +$0.04$3.83M$3.44M = Details
4/26/13 Q313 -$0.02-$0.15 +$0.13$25M$11.94M N/A Details
1/25/13 Q213 -$0.29-$0.25 -$0.04$2.6M$6.02M N/A Details
10/26/12 Q113 -$0.30-$0.25 -$0.05$4.1M$4.1M N/A Details